Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2008-07-08
2008-07-08
Kim, Jennifer (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
10712958
ABSTRACT:
The subject invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject in need of such treatment comprising administering to the subject R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof alone or in combination with 2-amino-6-trifluoromethoxy benzothiazole in amounts effective to treat ALS in the subject.
REFERENCES:
patent: 3513249 (1970-05-01), Gittos et al.
patent: 5387612 (1995-02-01), Youdim et al.
patent: 5444095 (1995-08-01), Tatton et al.
patent: 5453446 (1995-09-01), Youdim et al.
patent: 5457133 (1995-10-01), Youdim et al.
patent: 5486541 (1996-01-01), Sterling et al.
patent: 5519061 (1996-05-01), Youdim et al.
patent: 5527814 (1996-06-01), Louvel
patent: 5532415 (1996-07-01), Youdim et al.
patent: 5576353 (1996-11-01), Youdim et al.
patent: 5599991 (1997-02-01), Youdim et al.
patent: 5668181 (1997-09-01), Youdim et al.
patent: 5744500 (1998-04-01), Youdim et al.
patent: 5767164 (1998-06-01), Tatton et al.
patent: 5786390 (1998-07-01), Youdim et al.
patent: 5844003 (1998-12-01), Tatton et al.
patent: 5891923 (1999-04-01), Youdim et al.
patent: 6126968 (2000-10-01), Peskin et al.
patent: 6277886 (2001-08-01), Levy et al.
patent: 6316504 (2001-11-01), Youdim et al.
patent: 6630514 (2003-10-01), Youdim et al.
patent: 6635667 (2003-10-01), Thomas
patent: 6956060 (2005-10-01), Youdim et al.
patent: 2004/0010038 (2004-01-01), Blaugrund et al.
patent: 2004/0052843 (2004-03-01), Lerner et al.
patent: 2005/0093830 (2005-05-01), Youdim et al.
patent: 2006/0018957 (2006-01-01), Lerner et al.
patent: 2006/0094783 (2006-05-01), Youdim et al.
patent: 2006/0188581 (2006-08-01), Peskin
patent: 0538134 (1993-04-01), None
patent: 0436492 (1994-06-01), None
patent: WO95/11016 (1995-04-01), None
patent: 9518617 (1995-07-01), None
patent: 9637199 (1996-11-01), None
patent: 9712583 (1997-04-01), None
patent: 9802152 (1998-01-01), None
patent: WO03072055 (2003-09-01), None
patent: WO2004045515 (2004-06-01), None
patent: 2006057912 (2006-06-01), None
Kaal et al. Chronic mitochondrial inhibition induces selective motoneuron death in vitro: a new model for amyotrophic lateral sclerosis. Journal of Neurochemistry, 2000, 74(3) pp. 1158-1165.
Orru et al. Association of monoamine oxidase B alleles with age at onset in amyotrophic lateral sclerosis. Neuromuscular Disorder 9 (1999) pp. 593-597.
Turner MR, et al., (2001) The King's data base 1990-2000: An analysis of the effect on survival of interventions in ALS.ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43; and.
Traynor BJ, et al., (2001) Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995-2000.ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43-4.
Wong PC, et al., (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron diseases characterized by vacuolar degeneration of mitochondria.Neuron, 14:1105-16.
Bensimon G, et al., (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.N Engl J Med., 330(9):585-91.
Bentué-Ferrer D, et al., (1996) Monoamine Oxidase B Inhibitors.CNS Drugs., 6(3):217-36.
Doble A. (1996) The pharmacology and mechanism of action riluzole.Neurology, 47 (Suppl. 1):S233-41.
Eliash S, et al. (2001) Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats.J. Neural Transm.,108:909-23.
Ferrante RJ, et al., (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation.Ann. Neurol., 42:326-34.
“Guidance for Industry: In vivo drug metabolism/drug interaction studies—study design, data analysis, and recommendations for dosing and labeling,” U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Nov. 1999.
Gurney ME, et al., (1994) Motor neuron degeneration in mice that express a human superoxide dismutase mutation.Science, 264:1772-5.
Gurney ME, et al., (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis.Ann. Neurol., 39:147-57.
Huang W, et al., (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.Eur. J. Pharmacol., 336:127-35.
Kong J, et al., (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1.J. Neurosci.,18:3241-50.
Lacomblez L, et al., (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis.Lancet, 347:1425-31.
Lange DJ, et al., (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis.Arch Neurol., 55(1):93-6.
Ludolph AC, et al., (1999) Antiglutamate therapy in ALS—which is the next step?J. Neural Transm., 55(Suppl.):79-96.
Maruyama W, et al., (2000) Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022.J. Neural Transm., 60(Suppl):171-86.
Maruyama W, et al. (2001) Transfection-enforced bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol.J. Neurochem., 78:727-35.
Physicians Desk Reference (2002), p. 772-5.
Speiser Z, et al., (1999) Studies with rasagiline, a monamine oxidase-B inhibitor, in experimental focal ischemia in the rat.J. Neural Transm., 106:593-606.
Traynor BJ, et al., (2001) Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995-2000.ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43-4.
Turner MR, et al., (2001) The King's data base 1990-2000: An analysis of the effect on survival of interventions in ALS.ALS and Other Motor Neuron Disorders, 2(Suppl. 2):43.
Vielhaber S, et al., (2000) Mitochondrial DNA abnormalities in skeletal muscle patients with sporadic amyotrophic lateral sclerosis.Brain, 123:1339-48.
Wong PC, et al., (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron diseases characterized by vacuolar degeneration of mitochondria.Neuron, 14:1105-16; and.
Youdim MBH, et al., (2001) Rasagiline (N-propargyl-1R(+)-aminoindan), a selective and potent inhibitor of mitochondrial monoamine oxidase BBr. J. Pharmacol., 132:500-6.
U.S. Appl. No. 11/595,726, filed Nov. 10, 2006, Youdim et al.
U.S. Appl. No. 11/600,561, filed Nov. 15, 2006, Frenkel et al.
Finberg et al., (1981) “Selective Irreversible Propargyl Derivative Inhibitors of Monoamine Oxidase (MAO) without the Cheese Effect”Chem. Abstracts94:202499.
Finberg and Youdim, (1985) “Modification of Blood Pressure and Nictitating Membrane Response to Sympathetic Amines by Selective Monoamine Oxidase Inhibitors”Brit. J. Pharmac. 541-546.
Finberg et al. (1985) “Modification of Blood Pressure and Nictitating Membrane Response to Sympathetic Amides by Selective Monoamide Oxidase Inhibitors, Type A and B, in the Cat”Chem. Abstracts103:81618.
Mendleicz and M.B.H. Youdim (1987)Brit. J. Psychiat, 142:508-511.
Youdim et al.(1984)Progress in Medical Chemistry21:138-167.
Youdim et al. (1988) Handbook of Experimental Pharmacology vol. 90/I (1988) Chapter 3 Trendlenburg and Weiner, eds.
Munsat, T.L. (1981) “Amantadine and guanidine are ineffective in ALS”Neurology31:1054.
Naoi, M. et al. “Mitochondrial Permeability Transition Pores: A Target of Apoptosis Regulation by Rasagiline”, Abstracts of the Society for Neuroscience, Society for Neuroscience, Washington, DC, US, vol. 27, No. 1, p. 520, XP001189217.
Supplemental European Search Report of European Application No. EP 03 78 3422, date of completion Apr. 8, 2008.
Blaugrund Eran
Levy Ruth
Cooper & Dunham LLP
Kim Jennifer
Teva Pharmaceutical Industries Ltd.
White John P.
LandOfFree
Use of rasagiline with or without riluzole to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of rasagiline with or without riluzole to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of rasagiline with or without riluzole to treat... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3952446